RxDoctor Payments Data

Andrew Iwach, MD

Ophthalmology · San Francisco, CANPI 1871682088

Payments from drug & device makers

$47,150in general payments, 2019–2025

Across 158 payments — averaging $298.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$33K
  • Bausch & Lomb Americas Inc.$7K
  • NEW World Medical,inc.$2K
  • Alcon$1K
  • Thea Pharma Inc.$1K
  • AbbVie$1K
  • plus $2K from 9 others

What the payments were for

  • Consulting fees$8,61018%
  • Speaking & faculty fees$19,65042%
  • Grants$10,00021%
  • Travel & lodging$1,6604%
  • Food & beverage$6,69614%
  • Education$330%
  • Other$5011%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,150 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$555,421
Medicare patients
1,054
Services billed
5,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyzultaLatanoprostene Bunod426$166,608
RocklatanNetarsudil Mesylat/Latanoprost176$99,472
Alphagan PBrimonidine Tartrate214$79,208
LumiganBimatoprost249$78,863
RhopressaNetarsudil Mesylate136$70,199
SimbrinzaBrinzolamide/Brimonidine Tart194$62,182
Brinzolamide224$42,033
AzoptBrinzolamide73$33,255
Brimonidine Tartrate572$33,201
ZioptanTafluprost/Pf87$29,113
CombiganBrimonidine Tartrate/Timolol90$27,638
IyuzehLatanoprost/Pf66$27,491
Dorzolamide-TimololDorzolamide/Timolol/Pf178$26,535
RestasisCyclosporine41$24,338
Timolol MaleateTimolol Maleate/Pf71$23,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieAlphagan P, Lumigan, Combigan, Restasis$1,089$210,047594 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$7,160$183,384441 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$685$169,671312 claims
AlconSimbrinza, Azopt$1,347$95,436267 claims
Thea Pharma Inc.Iyuzeh$1,163$27,49166 claims
NovartisTravatan Z$46$8,35434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →